{"id":33070,"date":"2024-07-03T12:13:56","date_gmt":"2024-07-03T12:13:56","guid":{"rendered":"https:\/\/ibima.eu\/obicetrapib-and-cardiovascular-outcomes-a-placebo-controlled-double-blind-randomized-phase-3-study-to-evaluate-the-effect-of-10-mg-obicetrapib-in-participants-with-atherosclerotic-cardiovascular-di\/"},"modified":"2024-07-03T12:13:56","modified_gmt":"2024-07-03T12:13:56","slug":"obicetrapib-and-cardiovascular-outcomes-a-placebo-controlled-double-blind-randomized-phase-3-study-to-evaluate-the-effect-of-10-mg-obicetrapib-in-participants-with-atherosclerotic-cardiovascular-di","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/obicetrapib-and-cardiovascular-outcomes-a-placebo-controlled-double-blind-randomized-phase-3-study-to-evaluate-the-effect-of-10-mg-obicetrapib-in-participants-with-atherosclerotic-cardiovascular-di\/","title":{"rendered":"Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies."},"content":{"rendered":"
JUAN JOS\u00c9 G\u00d3MEZ DOBLAS – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – NEWAMSTERDAM PHARMA B.V.<\/p>","protected":false},"excerpt":{"rendered":"
JUAN JOS\u00c9 G\u00d3MEZ DOBLAS – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – NEWAMSTERDAM PHARMA B.V.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2267],"tags":[],"acf":[],"yoast_head":"\n